Genetic Investigation of Cancer Predisposition
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorThe University of Texas Health Science Center at San Antonio
About this trial
Clinical information and samples (blood, saliva, and tumor) will be collected from patients with multiple cancers and/or a family history of cancer as well as from affected and unaffected relatives; samples will be systematically sequenced and evaluated for candidate driver mutations.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Any age
Personal history (with documented diagnosis) of cancer before the age of 50
Personal history of more than one primary cancer
Documented diagnosis of cancer AND family history of that same cancer type or multiple other cancers that do not fit classical criteria of hereditary cancer syndromes
Disqualifiers
Established genetic diagnosis of a known hereditary cancer syndrome that is compatible with the clinical presentation
Incarcerated
Trial population
Individuals with a family history of cancer or with a personal history of multiple cancers that might suggest increased genetic predisposition, but for which an identifiable susceptibility mutation has not been detected.
Trial design
Design model
Family-based
Time perspective
Prospective
Treatments tested in this trial
DNA or RNA Sequencing
GeneticSamples will be used for whole exome (DNA) or RNA sequencing
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Identification of Rare Genetic Variant
Genetic screen detects a mutation that is likely responsible for tumor development
Time frame
through study completion- approximately 6-12 months2
Identification of somatic (tumor only) mutation
Genetic screen detects a mutation that is likely responsible for tumor development
Time frame
through study completion- approximately 6-12 months3
Identification of Rare Genetic Variant in family members
Genetic screen detects a mutation that is likely responsible for tumor development
Time frame
through study completion- approximately 6-12 monthsSecondary outcomes
1
Identification of clinical spectrum of the disease in families
Genetic and clinical analysis reveals clinical features not previously assigned to the disease
Time frame
through study completion- approximately 6-12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: